CRL Offers Clients Global Services Integrated Structure
Clinical Reference Laboratory Inc, (Kansas, USA) (‘CRL Global Services’), an independent clinical testing laboratory operation, now offers its clients an integrated and optimized infrastructure to support their global clinical trials following the establishment of an additional laboratory in Cambridgeshire, United Kingdom, late in 2009.
CRL Global Services brings together a network of clinical laboratories around the world to provide global logistics, consistent instrumentation, standardized laboratory safety-, and centralized biomarker testing. CRL Global Services’ integrated system supports early to late phase pharmaceutical drug development. CRL Global Services has European operations in the UK and a worldwide technology platform.
For the client, CRL Global Services’ system provides centralized global project set-up and management, centralized data management, reporting, and financial tracking. CRL Global Services also provides web-based project information tools – Web-OASIS™ for investigators, and Trials-OASIS™ for sponsors.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
